The number of infected Nigerians is rising daily, notwithstanding, this development is not discouraging impact investors from doing what they know how tod do best, which is to make investing moves that guaranty returns and socially sustainable. That is the case of Argentil Capital Partners and CDC Group both of which in the first two weeks of June 2020, supported the ambitions of Tempohousing Nigeria Limited and mPharma.

Argentil Capital Partners has provided additional debt and equity to Tempohousing Nigeria Limited (THN). THN is a specialist in the development of flexible and affordable residential and commercial spaces with the aid of modern prefabricated technology and cargotecture. Its products have disrupted traditional market segments in places where high building and land costs in urban areas have created difficulty for individuals and firms to access quality living and commercial workspaces.

According to the African Private Equity and Venture Capital Association (AVCA), THN is a fast-growing SME with revenue growth of over 53 percent CAGR from inception in 2012 to 2019. Tempohousing Nigeria was incorporated to meet the demand for affordable housing in Nigeria by leveraging on technology and expertise to create a Nigerian tailored solution to the housing problem. The housing units should be quick to build, easy to maintain, portable and most importantly affordable.

The disruptive impact of THN’s solutions was acknowledged when Argentil received Private Equity Africa’s Deal of the Year (Small Cap) 2019 for the THN investment. Argentil is currently fundraising for a new regional fund that will target investment opportunities in SMEs across a number of key growth sectors in West Africa with an immediate focus on Ghana, Liberia, Nigeria, and Sierra Leone.